Replication stress is a characteristic feature of cancer cells, which is resulted from sustained proliferative signaling induced by activation of oncogenes or loss of tumor suppressors. In cancer cells, oncogene-induced replication stress manifests as replication-associated lesions, predominantly double-strand DNA breaks (DSBs). An essential mechanism utilized by cells to repair replication-associated DSBs is homologous recombination (HR). In order to overcome replication stress and survive, cancer cells often require enhanced HR repair capacity. Therefore, the key link between HR repair and cellular tolerance to replication-associated DSBs provides us with a mechanistic rationale for exploiting synthetic lethality between HR repair inhibition and replication stress. Our studies showed that DNA2 nuclease is an evolutionarily conserved essential component of HR repair machinery. Here we demonstrate that DNA2 is indeed overexpressed in pancreatic cancers, one of the deadliest and more aggressive forms of human cancers, where mutations in the KRAS are present in 90%-95% of cases. In addition, depletion of DNA2 significantly reduces pancreatic cancer cell survival and xenograft tumor growth, suggesting the therapeutic potential of DNA2 inhibition. Finally, we develop a robust high-throughput biochemistry assay to screen for inhibitors of the DNA2 nuclease activity. The top inhibitors were shown to be efficacious against both yeast Dna2 and human DNA2. Treatment of cancer cells with DNA2 inhibitors recapitulates phenotypes observed upon DNA2 depletion, including decreased DNA end resection and attenuation of HR repair. Similar to genetic ablation of DNA2, chemical inhibition of DNA2 selectively attenuates the growth of various cancer cells with oncogene-induced replication stress. Taken together, our findings open a new avenue to develop a new class of anti-cancer drugs by targeting druggable nuclease DNA2. We 3 propose DNA2 inhibition as new strategy in cancer therapy by targeting replication stress, a molecular property of cancer cells that is acquired as a result of oncogene activation instead of targeting undruggable oncoprotein itself such as KRAS.
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Introduction
The finding that poly(ADP-ribose) polymerase (PARP) inhibitors, a new class of DNA repair inhibitors, specifically kill cancer cells with BRCA1 or BRCA2 mutations but are less cytotoxic to normal cells highlighted the promise of DNA repair inhibitors for targeted cancer treatment 7, 21 . This finding also provides proof of the principle that synthetic lethality interactions in the DNA repair network can be exploited for targeted cancer therapy. Early in the process of tumorigenesis, genetic alterations such as activation of oncogenes and loss of tumor suppressor genes are implicated in inducing replication stress by providing premalignant cells with excessive growth signals 4, 16 . In cancer cells, oncogene-induced replication stress manifests as a high level of DNA double-strand breaks (DSBs) due to stalling and collapse of DNA replication forks 22, 37 . A dramatic increase of replication stress and spontaneous DNA damage in cancer cells, which renders them more dependent on DNA repair for survival 18 . Among all DNA repair pathways, homologous recombination-mediate DNA repair (HR) is an essential mechanism utilized by cancer cells to repair replication-associated DSBs and thereby to overcome replication stress and survive. The key link between HR repair and cellular tolerance to replication-associated DSBs provides us with a mechanistic rationale for exploiting synthetic lethality between HR repair inhibition and replication stress in cancer cells.
Moreover, owing to their hyper-proliferative state, cancer cells are more vulnerable to killing by DNA damaging agents. Common cancer treatment strategies use untargeted radiomimetic chemotherapy or radiotherapy that induce a broad range of DNA lesions including DSBs. The ability of cancer cells to repair DNA damage lowers therapeutic efficacy, thus the simultaneous use of a DNA repair inhibitor holds great promise in sensitizing cancer cells to conventional chemo/radiotherapy. Inhibitors that target enzymes mediating base excision repair, nucleotide excision repair and other DNA repair pathways have been developed and are being evaluated in clinical trials 11, 17, 32 .
Therefore, identification of new HR repair inhibitors can open new avenues to cancer therapies 2, 3, 9, 16, 23, 30 .
An evolutionarily conserved protein DNA2 possesses 5' flap endonuclease and 3'-5' helicase activities and it plays an important role in DNA damage repair, homologous recombination, and DNA replication. The nuclease activity of DNA2 has several welldocumented cellular functions, while the biological role of its helicase activity remains enigmatic. Specifically, DNA2 mediates the resection of the 5' strand at DNA double strand break ends 12, 25, 26, 28, 34, 39, 40, 51 , an early step in homologous recombination, and also at stalled and regressed replication forks 29, 46 . Dna2 in fungi processes long 5' DNA flaps during the maturation of Okazaki fragments in lagging strand DNA synthesis 1, 8 , while human DNA2 plays an essential but as yet undefined role in DNA replication 20 .
Human DNA2 has an additional function in mitochondrial DNA maintenance 50 . Finally, the unstructured and regulatory N-terminal domain of yeast Dna2 was recently shown to regulate DNA damage response by activating the Mec1 kinase ((Mec1 is orthologus to human DNA damage checkpoint kinase ATR) 33 . Among these important biological functions of DNA2, the nucleolytic processing of the 5' strands at spontaneous DSBs or regressed replication forks seems to be the most relevant in alleviating replication stress.
Consistent with this notion, DNA2 is overexpressed via gene duplication in yeast upon
replication stress caused by the mec1-21 mutation 48 . Interestingly, similar to this observation in yeast cells, studies from our group and others have demonstrated that DNA2 is overexpressed in a broad spectrum of malignancies including breast cancer, ovarian cancer, lung cancer, prostate cancer, glioblastoma, pancreatic cancer, leukemia, colon cancer, melanoma, Lynch Syndrome, and hereditary nonpolyposis colorectal cancer 19, 42, 45 . DNA2 overexpression is needed for the tolerance of increased replication stress induced by oncogene activation such as H-Ras or cyclin E in osteosarcoma and breast cancer cells, and partial depletion of DNA2 reduces the tumorigenicity of breast cancer cells 42 . These results have raised the prospect of targeting DNA2 in cancer therapy.
Since the increased nuclease activity of DNA2 is required in yeast and cancer cells to overcome replication stress and DNA damage, for the first time, we developed a robust biochemistry-based screening method for chemical inhibitors of DNA2. We conducted initial screen with nearly 50,000 compounds and we tested efficacy of several candidate inhibitors in pancreatic and breast cancer cell lines with oncogene-induced replication stress. Treatment of cancer cells with the top DNA2 inhibitor recapitulates many phenotypes observed upon DNA2 depletion, and attenuates the growth of various cancer cells. Taken together, in this study, we developed a feasible high-throughput chemical screen assay to identify novel DNA repair inhibitors and more importantly we provided a new synthetic lethal strategy based on inhibition of HR repair by DNA2 inhibitors in cancer cells with oncogene-induced replication stress.
Results

Sensitivity of pancreatic cancer cells to DNA2 depletion
Pancreatic cancer is particularly deadly due to the lack of an effective treatment regimen.
Here, we investigated the expression levels and therapeutic potential of DNA2 depletion in pancreatic cancers, where 90-95% cases are associated with an activating mutation in the K-Ras oncogene 13, 24, 38 . Analysis of gene expression patterns in pancreatic cancers in the Oncomine database shows that DNA2 is significantly upregulated 42 . Consistently, an elevated DNA2 protein level was observed in pancreatic cancer patient specimens ( Figure 1a ). Moreover, patients with chronic pancreatitis expressed DNA2 at an elevated level in their pancreatic tissue ( Figure 1a ). To establish the relationship between the K-Ras oncogene and DNA2 expression, we analyzed a transgenic K-Ras G12D pancreatic cancer mouse model. Similar to pancreatic cancer patient specimens, the DNA2 protein level was greatly increased in K-Ras G12D -activated early pancreatic cancer lesions, suggesting that DNA2 overexpression is an early event during tumorigenesis ( Figure 1b ). Importantly, the depletion of DNA2 impaired the growth and survival of cells from two pancreatic cancer lines, and also led to increased senescence and apoptosis of these cells ( Figure 1c , Supplementary Figure S1a ). Consistent with in vitro cell culture findings, DNA2 knockdown significantly reduced tumor growth in the xenograft model (Supplementary Figure S1b ). Furthermore, our analyses showed increased staining of p-CHK1, a key molecule in DNA damage signaling, and reduced staining of Ki67, a maker of cell proliferation, in DNA2-depleted cells likely due to endogenous DNA damage (Supplementary Figure S1c ). Thus, DNA2 overexpression is a common theme in many cancer types including pancreatic cancer and inhibition of DNA2 reduces pancreatic cancer cell survival both in vitro and in vivo.
Isolation of yeast Dna2 inhibitors
We have presented evidence that DNA2 overexpression alleviates the impaired proliferation of U2OS and MCF10A cells after an activation of either H-Ras or cyclin E 42 , suggesting that DNA2 could be an effective target in cancer therapy. This prompted us to develop a simple screen for chemical inhibitors of DNA2. The screen entailed the use of oligonucleotide (dT) 30 having a reporter fluorescent moiety, 6-FAM TM on the 5' end, and the dark quenching group, Iowa Black ® FQ, on the 3' end. Additionally a second dark quencher ZEN TM was placed between the 9th and 10th base (Figure 2a ). The fluorescence emitted by 6-FAM TM is quenched by FRET, but it increases when DNA is degraded by Dna2. In the initial screen, compounds were tested at a fixed concentration of inhibitors (33.33 µM) with a sub-saturating amount (0.09 nM) of Dna2. The inhibitory activity of the compounds was determined as a reduction in fluorescent signal compared to the DMSO only control. The primary screen hits were selected based on a ≥50% inhibition of the Dna2 activity. We screened ~50,000 chemical compounds from six different libraries ( Supplementary Table S1 ) to identify chemical inhibitors of the Dna2 nuclease activity. Since we could not purify human DNA2 in amounts sufficient for a high throughput screen, the initial screen was performed with yeast Dna2 (yDna2), followed by testing top candidate compounds with human DNA2 (hDNA2). The DNA2 nuclease domain is well conserved among eukaryotes, and therefore we reasoned that inhibitors of yDna2 will likely also work with the human counterpart. The first screening round identified 184 compounds, corresponding to a hit rate of ~0.4%.
These compounds were subject to re-screening to confirm their efficacy and also to eliminate those compounds that also inhibit T5 nuclease. We were able to narrow yDna2specific candidate compounds down to 39 ( Supplementary Table S2 ).
We note that a number of the compounds listed in Supplementary Table S3 inhibited the activity of both yDna2 and T5 and are therefore non-specific. Interestingly, many of these nonspecific inhibitors interact with DNA and are already used in cancer therapy, including multiple drugs known to inhibit type II topoisomerases (e.g. Daunorubicin, Doxorubicin, Mitoxantrone). Here, we have provided evidence that these compounds also affect the activity of Dna2. Thus, in addition to inducing DSBs by blocking topoisomerase II, it is likely that these drugs affect the processing and repair of these DSBs by nucleases.
Cellular screen for the most potent DNA2 inhibitors
The biological effectiveness of the 39 compounds selected by re-screening was determined by measuring their half maximal inhibitory concentration (IC 50 ) biochemically and in a cell-based system using the 384-well platform ( Supplementary   Table S2 ). We used the cancer cell line U2OS, as cells of this lineage overexpress DNA2 significantly and are sensitive to partial DNA2 depletion 42 . We conducted the viability assay in duplicate on three separate occasions using a concentration range of 10 pM to 10 µM for each compound. Cell proliferation was determined using DAPI staining and microscopy. About ten compounds showed IC 50 values between <1 μM and 10 μM both in cells and in vitro ( Supplementary Table S2 ), and two of them, NSC-5195242 and NSC-105808 ( Figures 3a and b ) were selected for further analysis.
Inhibitory effect of NSC-5195242 and NSC-105808 on human DNA2
The initial inhibitor screen was done with yDna2, thus it was important to test whether NSC-5195242 and NSC-105808 would affect the activity of hDNA2. hDNA2, purified as described 14 , was first tested using the triply labeled substrate as above (Figure 2a ). We found a similar inhibitory effect on hDNA2 and comparable IC 50 values as determined for yDna2 ( Figure 3c ). Furthermore, we tested the impact of these two compounds in a reconstituted 5' DNA end resection assay including hDNA2, BLM, and RPA as described 14 and in 5' flap processing by hDNA2. Both compounds inhibited resection in the reconstituted system ( Figure 3d ) and also 5' flap processing (Supplementary Figure   S2 ). Considering that compound NSC-105808 shows a lower IC 50 in vitro and biologically, further tests were focused on this compound. We found that NSC-105808 has no effect on ATPase activity of DNA2, nor the ability of BLM to unwind DNA, nor does it affect DNA binding by DNA2 ( Supplementary Figure S2 ). Furthermore, NSC-105808 does not inhibit the nuclease activity of EXO1 (Supplementary Figure S2 ) which can also catalyze DNA ends resection. Together, these data provide further evidence that NSC-105808 specifically inhibits the nuclease activity of DNA2.
NSC-105808 interferes with DNA end resection and homologous recombination in cells, and suppresses the cisplatin sensitivity of FANCD2-/-cells
To test whether NSC-105808 inhibits proliferation of U2OS cells by targeting DNA2, we first examined whether the ectopic overexpression of DNA2 could reduce the negative effect of NSC-105808 on cell growth. An approximately 1.5-2.0-fold increase in DNA2 protein level was able to attenuate the negative impact of NSC-105808 on cell proliferation, supporting the idea that DNA2 is the target of NSC-105808 in cells (Supplementary Figure S3 ). DNA2 functions in DSB end resection and homologous recombination (e.g. 25, 26, 42 ), thus we asked whether NSC-105808 interferes with these biological processes. Similar to DNA2 knockdown, NSC-105808 (24 hr treatment) significantly reduced DSB repair by gene conversion or single stand annealing (SSA) as determined by using two GFP-based reporter assays (Figure 4a Figures S7 and 8 ). We note that longer (>48 hr) exposure to NSC-105808 causes cell death (Figure 3b ). To test DSB end resection, we followed phosphorylation of the ssDNA-binding protein RPA (p-RPA) as described previously 43 .
Cells were treated with the topoisomerase I inhibitor Camptothecin (CPT), which induces DNA nicks, reversed replication forks and single-ended DSBs. As shown in Figure 4b , NSC-105808 treatment significantly attenuated the accumulation of CPT induced p-RPA, suggesting an impairment of DSB end resection. We then confirmed this result by conducting chromatin fractionation and observed that NSC-105808 reduced p-RPA accumulation in the chromatin fraction with a concomitant enhancement in the γ-H2AX level, reflective of an accumulation of unrepaired DSBs (Figure 4c ). Altogether, the above results provide evidence that NSC-105808 interferes with DSB resection and homologous recombination in cells.
We wished to further verify the DNA2 specificity of NSC-105808 in cells. Previous work revealed that DNA2 depletion in FANCD2-deficient cells partially suppresses the sensitivity of these cells to cisplatin 31 . As shown in Figure 4d , FANCD2-/-cells were more sensitive to cisplatin treatment compared with control cells, and, importantly, a very low concentration of NSC-105808 lessened the cisplatin sensitivity of these cells.
Together, our results are consistent with the premise that DNA2 is the target of NSC-105808 in cells.
Oncogene induction renders cells susceptible to NSC-105808
DNA2 overexpression, often observed in cancer cells, has been proposed to alleviate oncogene-induced replication stress. Increased sensitivity of cancer cells to DNA2 depletion 42 can likely be explained by an increased amount of substrates that are processed by DNA2 nuclease/helicase. We therefore asked whether NSC-105808 can sensitize cancer cells to oncogene-induced replication stress. Initially, we compared the impact of our DNA2 inhibitor in pancreatic or breast cancer cells versus control cells Figure   5c ). Second, we used the E6/E7 oncoprotein to induce replication stress in nontransformed pancreatic ductal cells (DT-PD59) as previously described 6 . Again, sensitivity to NSC-105808 was higher in cells with oncoprotein-induced replication stress ( Figure 5d ). In addition, we also established an inducible K-Ras expression cell line using non-transformed pancreatic ductal HPDE cells (Supplementary Figure S9a) . Both MTT and colony formation assays showed that activation of K-Ras expression sensitized HPDE cells to NSC-105808 treatment (Supplementary Figure S9b and c ). Lastly, we tested a series of epithelial cell lines that represent different stages of breast cancer progression 15 
Discussion
During tumorigenesis, the activation of an oncogene or loss of a tumor suppressor gene leads to excessive growth signals and replication stress. Notably, about 30% of all cancers have an activating mutation in Ras and the vast majority (up to 95%) of pancreatic cancer patients harbor a mutation in K-Ras 13, 24, 38 . Unfortunately, thus far, no effective inhibitor of the K-Ras oncoprotein has reached the clinic. In this study, we have strived to test the efficacy of DNA2 nuclease inhibition in cancer cells that experience oncogene-induced replication stress. Since such stress is a common denominator among multiple cancer types, DNA2 inhibition could be an efficacious strategy to treat a broad spectrum of cancers. Besides targeting cancer cells with an activated oncogene, chemical inhibition of DNA2 may also be useful for sensitizing cells to DNA damage when combined with radiomimetic chemotherapy or radiation therapy. As we expected, recent studies reported that DNA2 inhibition can sensitize breast cancer cells to chemotherapy inducing DNA damage 36 . We developed a simple high-throughput screening assay for DNA2 inhibitors, which can screen compound collections in very small reaction volume and in general to screen for inhibitors of other nucleases. We identified several compounds with the ability to inhibit DNA2 in DNA incision and also in a reconstituted system of DNA end resection. The NSC-105808 compound inhibits DNA2 but not other tested nucleases, however additional cellular targets cannot be excluded. Importantly, NSC-105808 treatment recapitulates several phenotypes of cells with DNA2 depletion, such as attenuated DSB end resection, decreased homologous recombination, and suppression of the sensitivity of FANCD2 deficient cells to cisplatin 31 . DNA2 plays an important role in telomere replication 35 , thus the effect of NSC-105808 on telomere stability cannot be excluded. The inhibitor reduces the growth of various cancer cells, and specifically those cells in which replication stress is induced via oncogene activation. A similar range of IC 50 values for the NSC-105808 in vivo and in in vitro assay may indicate that even minimal inhibition of DNA2 in cells could be lethal to cells. In example a single unrepaired DSB is lethal for cells. Alternatively DNA2 sensitivity to the drug can be altered by cell specific features such as DNA2 posttranslational modifications. Together our work suggests that temporary inhibition of DNA2 nuclease represents a promising strategy in cancer therapy. 
Materials and Methods
Human cell cultures
Cell proliferation assay
Cell proliferation was measured by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide; Sigma) reduction (Supplementary Materials and Methods).
Colony-forming assay
Transfection and colony-forming assay were performed as previously described ( 42 , Supplementary Materials and Methods).
Senescence assay
The assay was performed with a senescence β-galactosidase staining kit (#9860; Cell Signaling) according to the manufacturer's protocol (Supplementary Materials and Methods). 
Flow cytometric analysis of apoptosis and BrdU incorporation
Gene conversion and SSA Repair Assays
The DR-GFP, pCAGGS, and pCBASce plasmids were kindly provided by Dr. Maria Jasin (Memorial Sloan-Kettering Cancer Center, New York, NY). U2OS cells containing a single copy of the HR repair reporter substrate DR-GFP were generated as previously described 41 . SSA reporter cells were kindly provided by Dr. Jeremy Stark (Beckman Research Institute of the City of Hope) 5 . Details in Supplementary Materials and Methods.
Immunofluorescent staining and chromatin fractionation
For the detection of DNA-damage-induced p-RPA34 (S4/S8), immunofluorescent staining, and the preparation of chromatin fractions and Western blot analyses were performed as described previously 41, 42 .
High throughput screen for inhibitors of DNA2
The screen entailed the use of oligonucleotide (dT) 30 Figure   2a ). Initial screen, it was performed with yeast Dna2 (yDna2) 40 . Then, the top candidate compounds were tested on hDNA2. Identical reaction conditions were used for assaying the nuclease activity of yDna2 and hDNA2. We note that yDna2 is more active on the ssDNA substrate than hDNA2, thus the experiment with ssDNA substrates were done corresponds to V 0 and "x" is the enzyme concentration (nM). All the compounds were dissolved in DMSO and DMSO alone was used as control; the final concentration of DMSO was at 3.33% for protein-based assay and 0.1% for cell based assay. The Z' value was calculated as previously described 49 . Cell proliferation was determined using DAPI staining followed by high-throughput microscopy in a 384 well plate setup. In brief, cells were fixed with formaldehyde, washed, and stained with DAPI and the number of nuclei in each well counted by automated microscopy. The data were analyzed as described 27 .
Nuclease substrates
The oligonucleotide PSOL6929 (TTCATGGCTTAGAGCTTAATTGCTGAATCT) was 5' end-labeled with γ 32 P-ATP (Perkin-Elmer) and T4 polynucleotide kinase (NEB 
